Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Summary of publications:
Publications (original articles or review articles) published in 2020 from OUS - Unit for Cell Signalling (Krauss)
5 publications found
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells
Commun Biol, 3 (1), 123
Tankyrase inhibition ameliorates lipid disorder via suppression of PGC-1α PARylation in db/db mice
Int J Obes (Lond), 44 (8), 1691-1702
Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor
J Med Chem, 63 (13), 6834-6846
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
Commun Biol, 3 (1), 196